Groundbreaking Research on XPro™ and Remyelination
INmune Bio, Inc. is at the forefront of innovation in the field of neuroscience with the recent publication of a pivotal study that showcases the potential of its treatment XPro™. This groundbreaking research is highlighted in Cell Reports, revealing that XPro1595 can significantly promote remyelination in an animal model suffering from demyelinating diseases. The research has significant implications for various central nervous system (CNS) diseases, including Alzheimer's disease.
Understanding the Role of XPro™
Myelin, the protective sheath surrounding nerve fibers, is crucial for the rapid transmission of electrical impulses between neurons. Damage to myelin can lead to severe disruptions in communication within the brain and is a contributing factor in many neurodegenerative diseases. The recent findings led by Dr. Leslie Probert emphasize how microglia, the residential immune cells of the CNS, transition from a harmful, demyelinating state to a reparative, remyelinating state thanks to the action of XPro™.
The Significance of the Findings
Dr. Probert states, “Our research identifies soluble TNF as a vital checkpoint in this process. By blocking this cytokine, we can shift microglia back to a protective role.” This revolutionary insight opens up new pathways for therapeutic approaches aimed at treating demyelinating conditions like multiple sclerosis and Alzheimer's disease.
Implications for Alzheimer’s Disease
The significance of this study reaches far into the realm of Alzheimer's disease, where recent insights suggest that demyelination may play an underestimated role in the progression of the illness. CEO RJ Tesi adds, “Our findings underlie the potential of XPro™ in combating Alzheimer's by reinstating glia function, which is essential for preserving cognitive health.”
A Look Ahead: Future Trials
INmune Bio is gearing up to release top-line cognitive results from a blinded randomized Phase II trial aimed at early patients suffering from Alzheimer's disease soon. With an eye on future clinical trials, the company remains committed to advancing its innovative therapies that utilize the innate immune system to tackle debilitating diseases.
Demyelination: A Hidden Marker in Disease Progression
Research has firmly established that demyelination occurs in crucial brain regions responsible for cognition in Alzheimer's patients. This demyelination is often linked to the presence of amyloid-beta plaques, indicating that myelin loss could either precede or coincide with the foundational changes characteristic of Alzheimer's. Notably, alterations in myelin density can even be detected before the onset of typical symptoms, suggesting that demyelination could serve as an early biomarker for the disease.
Underlying Mechanisms of Myelin Damage
Further studies have shown that oligodendrocyte dysfunction leads to the breakdown of myelin sheaths, potentially contributing to neuronal health deterioration. This breakdown may also exacerbate the generation of amyloid-beta, creating a pernicious cycle that accelerates neurodegeneration. Imaging techniques have demonstrated marked reductions in myelin integrity among patients with mild cognitive impairment, underscoring the pervasive impact of demyelination.
About INmune Bio Inc.
INmune Bio, Inc. (NASDAQ: INMB) is a publicly traded clinical-stage biotechnology firm focused on leveraging the innate immune system to develop pioneering treatments. The company boasts two main product platforms currently undergoing clinical trials. The first, a Dominant-Negative Tumor Necrosis Factor (DN-TNF) product line, aims to neutralize the effects of soluble TNF, known to drive innate immune dysfunction and contribute to several diseases. XPro, a key product in this line, is under investigation for its potential to treat patients with mild Alzheimer's disease. Other indications, including treatment-resistant depression and oncology applications, are on the horizon.
Contact INmune Bio
For media inquiries or more information, contact:
David Moss, CFO
(858) 964-3720
info@inmunebio.com
Daniel Carlson
Head of Investor Relations
(415) 509-4590
dcarlson@inmunebio.com
Frequently Asked Questions
What is the main finding of the study published by INmune Bio?
The primary finding indicates that XPro1595 promotes remyelination in an animal model of demyelinating disease, showing potential treatment avenues for CNS diseases.
How does XPro™ help in treating Alzheimer's disease?
XPro™ helps by converting detrimental microglia into supportive cells that can promote remyelination and enhance neuronal communication, essential for combating Alzheimer's.
What clinical trials is INmune Bio currently conducting?
INmune Bio is conducting a blinded randomized Phase II trial focusing on patients with early Alzheimer's disease, among others.
Why is demyelination significant in Alzheimer's disease?
Demyelination may occur in critical brain regions and can be associated with amyloid-beta plaques, suggesting it is a key aspect of Alzheimer’s pathology.
What is the potential future direction for INmune Bio and XPro™?
INmune Bio aims to advance XPro™ through clinical trials, exploring its potential in treating various diseases, including Alzheimer's and potentially other conditions.
